Listen to today's #NoPriorsPod to hear why the Chai Discovery team is bullish on biotech. Thank you to Sarah Guo for hosting Jack Dent and Joshua Meier.
🆕 #NoPriorsPod! AI and atomic-level structure prediction are accelerating drug discovery — turning a slow, empirical search process into something closer to molecular engineering. Joshua Meier and Jack Dent co-founders Chai Discovery chat their new bio foundation model, Chai-2. It enables zero-shot antibody discovery in a single 24-well plate — with a ~20% hit rate, compressing years of lab work into weeks. They talk what's next for Chai, what's still challenging, and why they're 𝐛𝐮𝐥𝐥𝐢𝐬𝐡 𝐨𝐧 𝐛𝐢𝐨𝐭𝐞𝐜𝐡
